Stockhub

Neurocrine Biosciences, Inc.: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

14 August 2022

13 August 2022

30 July 2022

  • curprev 11:5411:54, 30 July 2022‎ Chris talk contribs‎ 1,679 bytes +1,679‎ Created page with "Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-meth..." Tag: Visual edit
Retrieved from ‘https://stockhub.co/research/Neurocrine_Biosciences,_Inc.’